3/19/2024

Fluvoxamine Maleate Extended-Release Capsules

Products Affected - Description

- Fluvoxamine maleate extended release capsule, Par Pharmaceuticals, 100 mg, bottle, 30 count, NDC 10370-0175-11
- Fluvoxamine maleate extended release capsule, Par Pharmaceuticals, 150 mg, bottle, 30 count, NDC 10370-0176-11
- Fluvoxamine maleate extended release capsule, Teva, 100 mg, bottle, 30 count, NDC 00228-2848-03
- Fluvoxamine maleate extended release capsule, Teva, 150 mg, bottle, 30 count, NDC 00228-2849-03

Reason for the Shortage

- Par did not provide a reason for the shortage.
- Teva did not provide a reason for the shortage.

Available Products

- There are no presentations available

Estimated Resupply Dates

- Par has fluvoxamine 100 mg and 150 mg extended-release capsules on back order and the company cannot estimate a release date.
- Teva has fluvoxamine 100 mg and 150 mg extended-release capsules on back order and the company estimates a release date of late-March 2024.

Updated

Updated March 19, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 13, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.